Their data reported that 24 h treatments with 20 μM of Oroxylin A can inhibit the invasion, cell proliferation, migration, and EMT by inactivating the NF-κB signaling pathway in human breast cancer cells [91]. The gene discussed is NFKB1; the disease is breast carcinoma.